Heterocyclic compounds as RSV inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
1. A compound represented by Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
{circle around (A)} is selected from the group consisting of:
1) optionally substituted aryl;
2) optionally substituted heteroaryl;
3) optionally substituted arylalkyl;
4) optionally substituted heteroarylalkyl;
5) optionally substituted-C 3 -C 12 cycloalkyl-C 1 -C 6 alkyl; and
6) optionally substituted-C 3 -C 12 cycloalkenyl-C 1 -C 6 alkyl;
{circle around (C)} is aryl or heteroaryl;
L is —CONH—, —NHCO—, —NHCO 2 —, or —NHS(O) 2 —;
One of X and Y is selected from O, S, and NR 4 , and the other is N or CR 5 ;
Each R 1 and R 2 is independently selected from the group consisting of: halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C 1 -C 8 alkyl, and optionally substituted —C 1 -C 8 alkoxy;
Each R 3 is selected from the group consisting of:
1) halogen;
2) optionally substituted —C 1 -C 8 alkoxy;
3) optionally substituted —C 1 -C 8 alkyl;
4) optionally substituted —C 2 -C 8 alkenyl;
5) optionally substituted —C 2 -C 8 alkynyl;
6) optionally substituted —C 3 -C 12 cycloalkyl;
7) optionally substituted —C 3 -C 12 cycloalkenyl;
8) optionally substituted 3- to 12-membered heterocycloalkyl;
9) optionally substituted aryl;
10) optionally substituted heteroaryl;
11) optionally substituted arylalkyl;
12) optionally substituted aryloxy;
13) —C(O)R 12 ;
14) —C(O)NR 13 R 14 ;
15) —C(O)NR 11 S(O) 2 R 12 ;
16) —S(O) 2 NR 13 R 14 ;
17) —NR 13 R 14 ;
18) —NR 11 S(O) 2 R 12 ;
19) —NR 11 C(O)R 12 ;
20) —NR 11 C(O)NR 13 R 14 ; and
21) —NR 11 C(O)NHS(O) 2 R 12 ;
n is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
v is 0, 1, 2, or 3;
R 4 is hydrogen or optionally substituted —C 1 -C 8 alkyl;
R 5 is halogen or optionally substituted —C 1 -C 8 alkoxy;
R 12 at each occurrence is independently selected from the group consisting of:
1) Hydrogen;
2) Halogen;
3) Hydroxyl;
4) optionally substituted —C 1 -C 8 alkoxy;
5) optionally substituted —C 1 -C 8 alkyl;
6) optionally substituted —C 2 -C 8 alkenyl;
7) optionally substituted —C 2 -C 8 alkynyl;
8) optionally substituted —C 3 -C 8 cycloalkyl;
9) optionally substituted —C 3 -C 8 cycloalkenyl;
10) optionally substituted 3- to 8-membered heterocycloalkyl;
11) optionally substituted aryl;
12) optionally substituted arylalkyl;
13) optionally substituted heteroaryl; and
14) optionally substituted heteroarylalkyl; and
R 11 , R 13 and R 14 are each independently selected from hydrogen, optionally substituted —C 1 -C 8 -alkyl, optionally substituted —C 2 -C 8 -alkenyl, optionally substituted —C 2 -C 8 -alkynyl; optionally substituted —C 3 -C 8 -cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; alternatively R 13 and R 14 are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic ring.
2. The compound of claim 1 , wherein L is —CONH— or —NHCO—.
3. The compound of claim 1 , wherein {circle around (A)} is selected from the groups
by removal of one hydrogen atom, wherein each of the groups is optionally substituted.
4. The compound of claim 1 , wherein {circle around (C)} is selected from one of the following groups by removal of one hydrogen atom, wherein each of the groups is optionally substituted:
by removal of one hydrogen atom, wherein each of the groups is optionally substituted.
5. The compound of claim 1 , wherein R 3 is selected from the following groups
wherein each group is optionally substituted.
6. The compound of claim 1 , wherein
is represented by
where R is hydrogen or methyl.
7. The compound of claim 1 , represented by one of Formulas:
or a pharmaceutically acceptable salt thereof,
wherein {circle around (A)}, {circle around (C)}, R 1 , R 2 , R 3 , R 5 , n, m, and v are as defined in claim 1 .
8. The compound of claim 1 , represented by one of Formulas
or a pharmaceutically acceptable salt thereof,
wherein C, L, X, Y, R 1 , R 2 , R 3 , n, m, and v are as defined in claim 1 ; m1 is 0, 1, 2, 3 or 4; m2 is 0, 1 or 2; R 22 is selected from hydrogen and —CH 3 ; and each R 21 is independently selected from halogen, —NH 2 , optionally substituted —C 1 -C 3 alkyl, and optionally substituted —C 1 -C 3 alkoxy.
9. The compound of claim 1 , represented by one of the Formulas
or a pharmaceutically acceptable salt thereof, wherein X, Y, L, R 1 , R 2 , R 3 , n and m are as defined in claim 1 ; m1 is 0, 1, 2, 3 or 4; m2 is 0, 1 or 2; v′ is 0, 1, 2, or 3; v″ is 0, 1, or 2; R 22 is selected from hydrogen and —CH 3 ; and each R 21 is independently selected from halogen, —NH 2 , optionally substituted —C 1 -C 3 alkyl, and optionally substituted —C 1 -C 3 alkoxy.
10. A compound selected from the compounds set forth below, or a pharmaceutically acceptable salt thereof:
Compound
Structure
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
11. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.
12. A method of treating or preventing an RSV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds of claim 1 .
13. The method of claim 12 , further comprising the step of administering to the subject an additional anti-RSV agent.
14. The method of claim 12 , further comprising administering to the subject a steroid anti-inflammatory compound.
15. A method of treating RSV and influenza in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 and a therapeutically effective amount of an anti-influenza agent.
16. The method of claim 13 , wherein the compound and the additional anti-RSV agent are co-formulated.
17. The method of claim 13 , wherein the compound and the additional anti-RSV agent are co-administered.
18. The method of claim 13 , wherein administering the compound allows for administering of the additional anti-RSV agent at a lower dose or frequency as compared to the administering of the additional anti-RSV agent alone that is required to achieve similar results in prophylactically treating an RSV infection in a subject in need thereof.
19. The compound of claim 1 , wherein n is 1, 2 or 3 and each R 1 is independently halogen or optionally substituted C 1 -C 8 -alkyl.